Improved cardiovascular variables during acetate free biofiltration

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Renal Replacement Therapy

Background:

• Acetate-free biofiltration (AFB) is a renal replacement therapy known for good tolerance and efficiency.
• Bicarbonate hemodialysis (HD) reduced hypotensive episodes compared to acetate-based HD, attributed to improved myocardial contractility.
• The study aimed to assess if complete acetate absence in AFB further improves dialysis stability and cardiovascular health.

Purpose of the Study:

• To evaluate the impact of acetate-free biofiltration (AFB) on dialysis stability and cardiovascular parameters.
• To compare AFB with bicarbonate hemodialysis (HD) in a long-term randomized trial.
• To determine if eliminating acetate enhances hemodynamic stability and reduces left ventricular mass index.

Main Methods:

• A one-year randomized trial comparing 11 patients on AFB with 9 patients on HD.
• Patients were matched for age, sex, and urea reduction rate.
• Measurements included automated blood pressure, antihypertensive medication, M-mode echocardiography for left ventricular mass index (LVMi), and serum lipids.

Main Results:

• AFB demonstrated better control of pre-dialysis mean arterial pressure (MAP) compared to HD (p=0.01).
• Left ventricular mass index (LVMi) significantly decreased in the AFB group, while it increased in the HD group (p=0.03).
• Post-dialysis MAP remained stable in both groups, and the incidence of hypotensive episodes did not differ significantly.

Conclusions:

• AFB offers superior pre-dialysis MAP control and stable post-dialysis MAP compared to HD.
• AFB led to a significant reduction in left ventricular mass index (LVMi), suggesting cardiovascular benefits.
• The percentage of hypotensive dialyses was similar between AFB and HD, but AFB showed improved cardiac remodeling markers.